AR062613A1 - Formulacion de compuestos organicos - Google Patents

Formulacion de compuestos organicos

Info

Publication number
AR062613A1
AR062613A1 ARP070103869A ARP070103869A AR062613A1 AR 062613 A1 AR062613 A1 AR 062613A1 AR P070103869 A ARP070103869 A AR P070103869A AR P070103869 A ARP070103869 A AR P070103869A AR 062613 A1 AR062613 A1 AR 062613A1
Authority
AR
Argentina
Prior art keywords
formulation
organic compounds
drug compound
acidic drug
valsartan
Prior art date
Application number
ARP070103869A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39047776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR062613(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP06120038A external-priority patent/EP1897537A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR062613A1 publication Critical patent/AR062613A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Composiciones farmacéuticas que comprenden un compuesto de fármaco ácido que es un antagonista del receptor de angiotensina II o una forma liberable del mismo, y un modificador del pH. Reivindicacion 25: La composicion farmacéutica de acuerdo con cualquiera de las reivindicaciones anteriores, en donde el compuesto de fármaco ácido es valsartan.
ARP070103869A 2006-09-04 2007-08-31 Formulacion de compuestos organicos AR062613A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06120038A EP1897537A1 (en) 2006-09-04 2006-09-04 Composition comprising an angiotensin II receptor antagonist
EP07103396 2007-03-02

Publications (1)

Publication Number Publication Date
AR062613A1 true AR062613A1 (es) 2008-11-19

Family

ID=39047776

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103869A AR062613A1 (es) 2006-09-04 2007-08-31 Formulacion de compuestos organicos

Country Status (5)

Country Link
AR (1) AR062613A1 (es)
CL (1) CL2007002553A1 (es)
PE (1) PE20081364A1 (es)
TW (1) TW200817054A (es)
WO (1) WO2008028885A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
US20140127299A1 (en) * 2012-11-07 2014-05-08 NaZura BioHealth, Inc. GRAS Enteric Coating Formulations and Methods of Making and Using Same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
WO1999044590A1 (en) * 1998-03-04 1999-09-10 Takeda Chemical Industries, Ltd. Sustained-release preparation for aii antagonist, production and use thereof
EP1258254A4 (en) * 2000-02-21 2004-02-04 Takeda Chemical Industries Ltd COMPOSITIONS FOR DELAYED DELIVERY OF PHYSIOLOGICALLY ACTIVE COMPOUNDS THAT ARE LOW WATER-SOLUBLE, METHOD FOR THE PRODUCTION AND USE THEREOF
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
WO2005089720A1 (en) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Valsartan tablets and the process for the preparation thereof
CA2592091A1 (en) * 2004-12-24 2006-06-29 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan

Also Published As

Publication number Publication date
WO2008028885A2 (en) 2008-03-13
TW200817054A (en) 2008-04-16
WO2008028885A3 (en) 2008-05-02
PE20081364A1 (es) 2008-12-04
CL2007002553A1 (es) 2008-05-16

Similar Documents

Publication Publication Date Title
EA201070786A1 (ru) Бензофуропиримидиноны
BR122013025375B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
BRPI0915084B8 (pt) composto, e, composição farmacêutica
ECSP11011151A (es) Compuestos purina
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
RS54587B1 (en) IMINOTIADIAZINE-DIOXIDE COMPOUNDS AS BACE, MIXTURE, AND USE INHIBITORS
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
CL2007002916A1 (es) Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras.
EA201170772A1 (ru) Органические соединения
RS52874B (en) THYOPHEN ANALYSIS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
CL2007003138A1 (es) Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
GT200800214A (es) Antagonistas de los piridil amida de los canales de calcios de tipo t
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
RS54386B1 (en) ANTIVIRAL UNITS
EA201100037A1 (ru) Органические соединения
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
UY30778A1 (es) Compuestos de 5,6-dihidro-1h-piridin-2-ona
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
CR20110209A (es) Composición farmacéutica sólida
CL2011000165A1 (es) Compuestos derivados de indolinonas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento y/o la prevencion del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
PA8691901A1 (es) Composicion farmaceutica solida que comprende 1-(4-cloro-anilino)-4-(4-piridil-metil)-ftalazina y un modificador del ph
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CL2008003266A1 (es) Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales.
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.

Legal Events

Date Code Title Description
FB Suspension of granting procedure